Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 2, 2018
Event: Entry into a Material Definitive Agreement for a registered direct offering of securities.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 2,892,000 Units to three investors.
- Unit Composition: One share of common stock (par value $0.012) and one warrant to purchase one share.
- Offering Price: $6.25 per Unit.
- Warrant Terms: Exercise price of $7.25 per share; exercisable commencing six months after issuance for a period of three and one-half years.
- Expected Net Proceeds: Approximately $16,500,000 (after deducting placement agent fees, expenses, and estimated offering expenses).
- Placement Agent Fees: H.C. Wainwright & Co., LLC to receive 7% of gross proceeds as a fee, 1% as a management fee, up to $50,000 for non-accountable expenses, and warrants to purchase up to 115,680 shares (exercise price $7.8125).
Material Changes and Outlook
Expected Closing: The sale of Units is expected to close on or about July 6, 2018, subject to customary closing conditions.
Forward-Looking Statements: The filing contains forward-looking statements regarding the closing date and proceeds. The Company notes that the closing is subject to conditions and contingencies; if not satisfied, the Offering may not close.
Financial Performance: This filing does not provide revenue, profit, cash flow, margin, or debt metrics. It focuses solely on the capital raise transaction.
Investor Verification Checklist
- Verify the actual closing date of the Offering (expected July 6, 2018) and confirm if all customary conditions were satisfied.
- Confirm the final net proceeds received by the Company after all fees and expenses.
- Review the impact of the new share issuance and warrant exercises on existing shareholder dilution.
- Monitor the Company's use of the approximately $16.5 million in net proceeds as disclosed in subsequent filings.